Thermo Fisher Scientific Inc (NYSE:TMO) – Stock analysts at Leerink Swann decreased their FY2017 earnings estimates for Thermo Fisher Scientific in a research report issued to clients and investors on Monday. Leerink Swann analyst P. Souda now anticipates that the medical research company will post earnings per share of $9.33 for the year, down from their previous estimate of $9.34. Leerink Swann currently has a “Outperform” rating and a $200.00 target price on the stock. Leerink Swann also issued estimates for Thermo Fisher Scientific’s Q1 2018 earnings at $2.36 EPS, Q2 2019 earnings at $2.82 EPS, Q3 2019 earnings at $2.83 EPS and FY2019 earnings at $11.24 EPS.
Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The company had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $5.03 billion. During the same period in the prior year, the firm posted $2.03 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 13.9% on a year-over-year basis.
Several other brokerages also recently commented on TMO. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $212.00 price objective on the stock in a research report on Thursday, September 21st. Cowen reissued an “outperform” rating and set a $220.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Sunday, September 10th. Deutsche Bank set a $226.00 price objective on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Thursday, October 26th. Barclays reissued an “overweight” rating and set a $215.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Monday, September 25th. Finally, Goldman Sachs Group began coverage on shares of Thermo Fisher Scientific in a report on Tuesday, September 26th. They set a “buy” rating and a $225.00 price target on the stock. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $205.21.
Shares of Thermo Fisher Scientific (NYSE TMO) opened at $185.63 on Wednesday. Thermo Fisher Scientific has a 1 year low of $139.88 and a 1 year high of $201.20. The company has a market cap of $73,161.61, a PE ratio of 20.05, a P/E/G ratio of 1.67 and a beta of 1.06. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.81 and a current ratio of 1.26.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. AXA boosted its holdings in shares of Thermo Fisher Scientific by 9.2% in the third quarter. AXA now owns 772,234 shares of the medical research company’s stock worth $146,107,000 after buying an additional 65,083 shares during the last quarter. Steward Partners Investment Advisory LLC bought a new stake in Thermo Fisher Scientific during the 3rd quarter worth approximately $1,634,000. Public Employees Retirement System of Ohio raised its stake in Thermo Fisher Scientific by 1.9% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 412,534 shares of the medical research company’s stock worth $78,051,000 after acquiring an additional 7,528 shares during the period. Americafirst Capital Management LLC bought a new stake in Thermo Fisher Scientific during the 3rd quarter worth approximately $876,000. Finally, Moors & Cabot Inc. raised its stake in Thermo Fisher Scientific by 36.5% during the 3rd quarter. Moors & Cabot Inc. now owns 3,644 shares of the medical research company’s stock worth $686,000 after acquiring an additional 975 shares during the period. 86.16% of the stock is currently owned by institutional investors.
In other news, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the sale, the chief executive officer now owns 252,577 shares of the company’s stock, valued at approximately $47,582,981.03. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.49% of the company’s stock.
The business also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.32%. The ex-dividend date of this dividend is Thursday, December 14th. Thermo Fisher Scientific’s payout ratio is presently 10.19%.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.thestockobserver.com/2017/12/08/leerink-swann-analysts-cut-earnings-estimates-for-thermo-fisher-scientific-inc-tmo.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.